Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
AAREYDRUGS

Aarey Drugs & Pharmaceuticals Share Price

 
Stock Hit Upper Circuit

 

Aarey Drugs & Pharmaceuticals live price: ₹75.02. It opened at ₹74 vs previous close ₹71; intraday high/low: ₹75/₹72. The 50 & 200 DMA stand at ₹66.64/₹68.75.

Aarey Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹72
  • Today's High
  • ₹75
  • 52 Week Low
  • ₹48
  • 52 Week High
  • ₹100
  • Open Price₹74
  • Previous Close₹71
  • Volume179,852
  • 50 DMA₹66.64
  • 100 DMA₹69.04
  • 200 DMA₹68.75

Aarey Drugs & Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 15.1%
  • Over 3 Month + 16.54%
  • Over 6 Month -11.9%
  • Over 1 Year + 49.09%

Smart Investing Starts Here Start SIP with Aarey Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Aarey Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 61.9
  • PEG Ratio
  • -1.6
  • Market Cap Cr
  • 213
  • P/B Ratio
  • 1.4
  • Average True Range
  • 4.33
  • EPS
  • 1.21
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.88
  • RSI
  • 62.45
  • MFI
  • 59.96

Aarey Drugs & Pharmaceuticals Financials

Aarey Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹75.02
+ 3.56 (4.98%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹64.74
  • 50 Day
  • ₹66.64
  • 100 Day
  • ₹69.04
  • 200 Day
  • ₹68.75

Resistance and Support

73.88 Pivot Speed
  • R3 79.61
  • R2 77.32
  • R1 76.17
  • S1 72.73
  • S2 70.44
  • S3 69.29

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarey Drugs & Pharms. has an operating revenue of Rs. 390.90 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 1% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 6% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 19 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarey Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-11 Quarterly Results
2025-11-13 Quarterly Results
2025-08-13 Quarterly Results
2025-05-30 Audited Results
2025-02-14 Quarterly Results

Aarey Drugs & Pharmaceuticals F&O

Aarey Drugs & Pharmaceuticals Shareholding Pattern

39.06%
3.86%
45.39%
11.69%

Aarey Drugs & Pharmaceuticals FAQs

Aarey Drugs & Pharmaceuticals share price is ₹75 As on 15 April, 2026 | 21:06

The Market Cap of Aarey Drugs & Pharmaceuticals is ₹212.7 Cr As on 15 April, 2026 | 21:06

The P/E ratio of Aarey Drugs & Pharmaceuticals is 61.9 As on 15 April, 2026 | 21:06

The PB ratio of Aarey Drugs & Pharmaceuticals is 1.4 As on 15 April, 2026 | 21:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23